Pcas

Q1 2021 Net Sales

Ecully, France – April 21, 2021

Q1 2021 NET SALES

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as at March 31, 2021.

The PCAS Group had generated consolidated net sales of €51.8 million as of March 31, 2021, representing a decrease of 2.8% compared to the same period of the previous financial year (-0.8% at a constant exchange rate).

In millions of euros		2021		2020		% change		2021 At a constant exchange rate		% change
Sales as of 31 March		51.8		53.3		-2.8%		52.9		-0.8%
Pharmaceutical Synthesis		35.3		36.2		-2.6%		36.2		0.0%
Fine Specialty Chemicals		16.5		17.1		-3.3%		16.7		-2.5%

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business in Health generated sales of €35.3 million, down 2.6% on 2020 (stable at a constant exchange rate). R&D activity was up sharply in the first quarter (+60%), confirming the recovery expected following the slowdown in clinical trials during the health crisis in 2020. On the other hand, efforts made in response to the Covid-19 health emergency, in particular the production of hand sanitizer sold under the Naaha brand, had generated significant sales in the first quarter of 2020 which were not repeated on the same scale in the first quarter of 2021. This first quarter of 2021 also marked the launch of sales of Estetrol to Mithra. Estetrol is produced in the new highly potent pharmaceutical drug production workshop at the Villeneuve-la-Garenne site, which was inaugurated in September 2020.